Thyroid function
TSH and free T4 may be appropriate when symptoms raise concern for thyroid dysfunction.
Women’s Hormone Health
Changes in energy, sleep, mood, mental clarity, sexual health, and physical well-being can raise questions about hormonal health—particularly during perimenopause and the years following menopause. At Maine Performance & Longevity Center, we provide individualized hormone health evaluations for women in Hampden and throughout the Greater Bangor area. We begin by understanding what has changed, considering where you may be in the menopause transition, and evaluating other factors that may be contributing to your symptoms. Your symptoms deserve an evaluation—not an assumption.
Schedule your consultationUnderstanding hormonal changes
Perimenopause is the transition leading up to menopause, when ovarian hormone production becomes more variable and menstrual cycles may begin to change. This transition commonly begins in the 40s, although some women experience changes earlier.
Menopause is reached after 12 consecutive months without menstruation, when no other cause explains the absence of periods. It occurs at an average age of approximately 51 in the United States.
Postmenopause refers to the years following menopause. Although hormone fluctuations generally become less pronounced, lower estrogen levels can continue to influence symptoms, vaginal and urinary health, and bone health.
These changes are a normal part of aging, but symptoms that affect your quality of life deserve attention.
Symptoms deserve an evaluation
Hormonal changes do not always begin with hot flashes or an obvious change in menstrual cycles.
Possible symptoms include:
Not every symptom is caused by hormonal changes. Thyroid disorders, anemia, sleep disorders, medications, mood disorders, metabolic health, and other medical conditions can produce overlapping symptoms.
The goal is not simply to attribute symptoms to menopause. It is to understand what may be contributing and determine what deserves attention.
Evaluation before treatment
During perimenopause, several hormone levels—particularly estradiol (estrogen) and follicle-stimulating hormone (FSH)—can fluctuate significantly, sometimes from one day to the next. Because of these fluctuations, a single laboratory measurement may not reliably identify where you are in the menopause transition or explain the symptoms you're experiencing.
For most women age 45 and older, perimenopause and menopause can be identified through menstrual history, symptoms, and clinical evaluation without routine hormone testing. For women under 45, particularly those experiencing early menstrual changes or menopausal symptoms, additional testing may be appropriate.
At MPLC, we consider your age, menstrual patterns, symptoms, medical history, medications, contraception needs, personal and family risk factors, and overall health before deciding whether additional testing is useful.
TSH and free T4 may be appropriate when symptoms raise concern for thyroid dysfunction.
Can help evaluate anemia or iron deficiency, particularly when fatigue or heavy menstrual bleeding is present.
Glucose, HbA1c, lipid markers, and other testing may help assess broader health risks and identify contributing factors.
May be useful in selected circumstances, such as suspected early menopause or when the diagnosis is uncertain. Routine testing is not necessary for most women with typical menopausal symptoms.
May be considered when evaluating specific sexual health concerns or before appropriately selected testosterone therapy. These measurements do not independently diagnose the cause of low sexual desire.
Looking beyond hormones
Changes in sleep, physical activity, nutrition, stress, body composition, medications, and underlying medical conditions may contribute to how you feel during this stage of life.
At MPLC, we consider these factors alongside the menopause transition. Depending on your symptoms and goals, addressing sleep, resistance training, nutrition, metabolic health, or other contributing conditions may be an important part of your care.
Treatment should address the individual—not simply a hormone level.
Treatment when appropriate
Menopausal hormone therapy (MHT), also commonly referred to as hormone replacement therapy (HRT), is a treatment option that may help appropriately selected women experiencing bothersome menopausal symptoms.
Systemic estrogen therapy is the most effective treatment for hot flashes and night sweats and can also help with related sleep disruption. For women who have a uterus, progesterone or another appropriate progestogen is generally needed alongside systemic estrogen to protect the uterine lining.
Treatment may include transdermal estrogen, such as a patch, or other approved formulations depending on your individual needs and medical history.
For vaginal dryness, painful intercourse, recurrent urinary tract infections, or other genitourinary symptoms associated with menopause, local vaginal estrogen or other targeted treatments may be appropriate, even when systemic hormone therapy is not needed.
The goal is not simply to replace hormones. It is to improve symptoms and quality of life using treatment that is appropriate for you.
Individualized treatment decisions
The potential benefits and risks of menopausal hormone therapy depend on factors such as age, time since menopause, personal medical history, cardiovascular and blood clot risk, breast health, and the formulation and route of treatment.
For many healthy women experiencing bothersome menopausal symptoms, the benefits of menopausal hormone therapy (MHT) generally outweigh the risks, particularly when treatment begins before age 60 or within 10 years of menopause.
Age alone does not determine whether treatment is appropriate or when it should be discontinued. Decisions about starting or continuing MHT should consider your symptoms, medical history, individual risk factors, and treatment goals, with ongoing reassessment of benefits and risks.
However, certain conditions—including unexplained vaginal bleeding, a history of estrogen-sensitive cancer, blood clots, stroke, or significant liver disease—may make systemic hormone therapy inappropriate or require additional evaluation.
Nonhormonal prescription treatments and other strategies may be considered when MHT is not appropriate or not preferred.
Sexual Health Matters
Changes in sexual desire are common during perimenopause and after menopause and can significantly affect quality of life. Hormonal changes, sleep disturbances, mood, medications, relationship factors, and vaginal discomfort may all contribute.
Testosterone therapy may be an effective treatment option for appropriately selected women experiencing persistently low sexual desire. The strongest evidence supports its use in postmenopausal women with hypoactive sexual desire disorder (HSDD), following a comprehensive evaluation of potential contributing factors.
At MPLC, we evaluate sexual health concerns individually and consider testosterone therapy when clinically appropriate, with careful attention to dosing, potential risks, and ongoing monitoring.
The goal isn't simply to raise testosterone levels. It's to determine whether treatment can meaningfully improve sexual health and quality of life.
Contraception and menstrual changes
During perimenopause, menstrual cycles can become irregular, but ovulation and pregnancy may still occur.
Menopausal hormone therapy is not contraception.
For women who still need pregnancy prevention, contraceptive options and symptom management should be considered together.
Heavy, prolonged, unusually frequent, or otherwise concerning vaginal bleeding also deserves evaluation rather than automatically being attributed to perimenopause.
Follow-up matters
Starting treatment is not the end of the evaluation. We follow your symptoms, treatment response, side effects, and overall health to determine whether the plan is helping. Depending on the treatment selected, follow-up may include:
Are sleep, hot flashes, sexual health, and other symptoms improving? Is treatment making a meaningful difference in how you feel?
Monitoring may include blood pressure, cholesterol, and other cardiometabolic risk factors, as hormone therapy can influence these measurements depending on the treatment used.
Unexpected or persistent vaginal bleeding requires evaluation. We also emphasize the importance of staying current with recommended preventive screenings, including mammograms and cervical cancer screening (Pap tests and/or HPV testing), based on your age, medical history, and individual risk factors.
Routine estrogen or progesterone testing is generally unnecessary during standard MHT. For women receiving testosterone therapy, laboratory monitoring helps guide safe dosing and avoid excessive hormone levels.
We monitor potential side effects, changes in your health, and any new concerns that may require adjusting or reconsidering treatment.
Treatment should continue to have a reason
If symptoms do not improve as expected, that matters. We reassess whether the treatment is addressing the right problem, whether another contributing factor deserves attention, and whether adjustments or alternative approaches would be more appropriate.
Treatment may be continued, adjusted, or discontinued based on your response, preferences, changing health risks, and ongoing goals.
The goal is not simply to prescribe treatment. It is to determine whether treatment is meaningfully improving your health and quality of life.
Written or medically reviewed by Zachary Greenier, MMSc, PA-C.
Your next step
Begin with a comprehensive Executive Health Consultation designed to understand your symptoms, evaluate your overall health, and determine what deserves attention.